LivaNova (NASDAQ:LIVN) Announces Earnings Results

LivaNova (NASDAQ:LIVN) issued its quarterly earnings results on Wednesday. The company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.17, FiscalAI reports. The business had revenue of $393.10 million for the quarter, compared to analysts’ expectations of $381.13 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period last year, the business earned $1.11 earnings per share.

Here are the key takeaways from LivaNova’s conference call:

• Broad-based growth led to higher guidance. Third-quarter revenue rose 10% to $393 million, and LivaNova raised its 2026 revenue growth outlook to 9%–10% and adjusted EPS outlook to $4.40–$4.50.
• Cardiopulmonary growth and capacity expansion are supporting further gains. Segment revenue increased 11%, with strength in heart-lung machines and consumables; a new oxygenator line is operational, and the company expects double-digit output growth in 2027.
• Epilepsy momentum strengthened. Revenue grew 11%, supported by higher volume and realized pricing, clinical evidence, and improved reimbursement; LivaNova raised its 2026 epilepsy growth outlook to 8%–9%.
• OSA remains a key future growth opportunity, though commercialization is still ahead. The company cited differentiated clinical results and new category CPT codes expected to take effect in 2028, while planning a limited launch in 2027 and larger commercial investment beginning in 2028.
• Investment and working-capital needs weighed on cash generation. Quarterly adjusted free cash flow fell to $56 million from $62 million a year earlier, while capital spending increased; full-year adjusted free cash flow guidance was maintained at $140 million–$160 million.

LivaNova Trading Up 20.4%

Shares of LivaNova stock traded up $16.28 during trading on Wednesday, reaching $96.18. 2,571,488 shares of the stock were exchanged, compared to its average volume of 738,652. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The stock’s fifty day moving average is $78.56 and its 200 day moving average is $73.10. The firm has a market cap of $5.30 billion, a price-to-earnings ratio of 28.52 and a beta of 0.91. LivaNova has a 1 year low of $48.82 and a 1 year high of $99.38.

Trending Headlines about LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Quarterly results beat expectations: LivaNova reported adjusted earnings of $1.23 per share, above estimates of $1.03–$1.06 and up from $1.11 a year earlier. Revenue rose 9.9% year over year to $393.1 million, exceeding analyst forecasts of about $381 million. LivaNova Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Full-year outlook improved: The company raised its full-year EPS guidance, signaling increased confidence in its earnings outlook. LivaNova Beats Q3 Estimates and Raises Full-Year EPS Guidance
• Positive Sentiment: Analyst sees more upside: Needham raised its price target to $112 from $93 and maintained a Buy rating, reflecting a more favorable view of the shares. Needham & Company recommendations

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on LIVN shares. Barclays upgraded shares of LivaNova to a “strong-buy” rating in a report on Wednesday, October 7th. Zacks Research lowered shares of LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Mizuho lifted their target price on shares of LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a research note on Wednesday, August 5th. Finally, Needham & Company LLC upped their price target on shares of LivaNova from $93.00 to $112.00 and gave the company a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and a consensus price target of $90.12.

Insider Transactions at LivaNova

In other LivaNova news, Director Brooke Story sold 2,300 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the transaction, the director owned 7,488 shares of the company’s stock, valued at $609,672.96. This represents a 23.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the completion of the sale, the director owned 4,434 shares of the company’s stock, valued at approximately $345,896.34. This trade represents a 44.11% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 7,450 shares of company stock worth $591,839. 0.35% of the stock is owned by company insiders.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.